Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation

Immune checkpoint inhibitor therapies and allogeneic hematopoietic cell transplant (alloHCT) represent two distinct modalities that offer a chance for long-term cure in a diverse array of malignancies and have experienced many breakthroughs in recent years. Herein, we review the CD27-CD70 co-stimula...

Descripción completa

Detalles Bibliográficos
Autores principales: Lutfi, Forat, Wu, Long, Sunshine, Sarah, Cao, Xuefang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493876/
https://www.ncbi.nlm.nih.gov/pubmed/34630390
http://dx.doi.org/10.3389/fimmu.2021.715909

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8493876/
https://www.ncbi.nlm.nih.gov/pubmed/34630390
http://dx.doi.org/10.3389/fimmu.2021.715909

Ejemplares similares